Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|June 23, 2021
Finally, Effective Inhibitors of Mutant KRASNeal Rosen
Pigment Cell & Melanoma Research|October 27, 2010
Oncogenic RAF: a brief history of timeDavid Solit, Neal Rosen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2008
Determinants of RASistance to anti-epidermal growth factor receptor agentsJosé Baselga, Neal Rosen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Targeting HER2 in prostate cancer: where to next?David B Solit, Neal Rosen
The New England Journal of Medicine|July 13, 2022
Targeting Oncogenic RAS ProteinDan L Longo, Neal Rosen
Breast Cancer Research and Treatment|June 29, 2002
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancerM M Moasser, Neal Rosen
The New England Journal of Medicine|February 25, 2011
Resistance to BRAF inhibition in melanomasDavid B Solit, Neal Rosen
Cancer Cell|January 22, 2011
Mutant BRAF melanomas--dependence and resistancePoulikos I Poulikakos, Neal Rosen
Cancer Discovery|January 10, 2014
Towards a unified model of RAF inhibitor resistanceDavid B Solit, Neal Rosen
Cancer Cell|October 19, 2006
AKT and cancer--is it all mTOR?Neal Rosen, Qing-Bai She
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|June 23, 2021
Finally, Effective Inhibitors of Mutant KRASNeal Rosen
Pigment Cell & Melanoma Research|October 27, 2010
Oncogenic RAF: a brief history of timeDavid Solit, Neal Rosen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2008
Determinants of RASistance to anti-epidermal growth factor receptor agentsJosé Baselga, Neal Rosen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Targeting HER2 in prostate cancer: where to next?David B Solit, Neal Rosen
The New England Journal of Medicine|July 13, 2022
Targeting Oncogenic RAS ProteinDan L Longo, Neal Rosen
Breast Cancer Research and Treatment|June 29, 2002
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancerM M Moasser, Neal Rosen
The New England Journal of Medicine|February 25, 2011
Resistance to BRAF inhibition in melanomasDavid B Solit, Neal Rosen
Cancer Cell|January 22, 2011
Mutant BRAF melanomas--dependence and resistancePoulikos I Poulikakos, Neal Rosen
Cancer Discovery|January 10, 2014
Towards a unified model of RAF inhibitor resistanceDavid B Solit, Neal Rosen
Cancer Cell|October 19, 2006
AKT and cancer--is it all mTOR?Neal Rosen, Qing-Bai She
Pageof 21